Polymorphism in IL1B-ILIB-511 association with tuberculosis and decreased lipopolysaccharide-induced IL-1β in IFN-γ primed ex-vivo whole blood assay

被引:38
作者
Awomoyi, AA
Charurat, M
Marchant, A
Miller, EN
Blackwell, JM
McAdam, KPWJ
Newport, MJ
机构
[1] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[2] MRC Labs, Banjul, Gambia
[3] Univ Maryland Biotechnol Inst, Inst Human Virol, Baltimore, MD USA
[4] Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Cambridge, England
[5] Brighton & Sussex Med Sch, Dept Med, Brighton, E Sussex, England
来源
JOURNAL OF ENDOTOXIN RESEARCH | 2005年 / 11卷 / 05期
基金
英国惠康基金;
关键词
IL1B polymorphism; interleukin-1b; tuberculosis; ex-vivo whole blood assay;
D O I
10.1179/096805105X58706
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To determine whether variation in two interleukin 1 family genes (IL1B and interleukin 1 receptor antagonist, IL1RN) is associated with pulmonary tuberculosis (TB), two published polymorphisms at nucleotide positions -511 and +3953 in IL1B and one in the IL1RN 86 bp VNTR were genotyped in 335 smear positive Gambian TB patients, and 298 ethnically matched controls. All individuals were HIV negative. Decreased risk of pulmonary TB was associated with both heterozygosity and homozygosity for the IL1B-511-C allele (OR 0.66, P = 0.027, and OR 0.58, P = 0.015, respectively). Nonetheless, the C allele was present at a frequency of 0.66 in TB cases suggesting that whilst IL-1 beta contributes to disease susceptibility, it is not the major factor. There was no association between the IL1B+3953-T/C polymorphism or the 86 bp IL1RN pentallelic repeat and TI3 in this population. Using an ex-vivo whole blood assay, healthy Gambian individuals who are homozygous for the IL1B-511-T allele failed to exhibit a significant increase in IL-1 beta production in response to LPS after IFN-gamma priming.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 27 条
[1]   Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis [J].
Awomoyi, AA ;
Marchant, A ;
Howson, JMM ;
McAdam, KPWJ ;
Blackwell, JM ;
Newport, MJ .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (12) :1808-1814
[2]  
Bellamy R., 1998, Tubercle and Lung Disease, V79, P83, DOI 10.1054/tuld.1998.0009
[3]   ASSOCIATION OF GRAVES-DISEASE WITH AN ALLELE OF THE INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE [J].
BLAKEMORE, AIF ;
WATSON, PF ;
WEETMAN, AP ;
DUFF, GW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (01) :111-115
[4]   INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AS A DISEASE SEVERITY FACTOR IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BLAKEMORE, AIF ;
TARLOW, JK ;
CORK, MJ ;
GORDON, C ;
EMERY, P ;
DUFF, GW .
ARTHRITIS AND RHEUMATISM, 1994, 37 (09) :1380-1385
[5]   MULTIPLE SIGNIFICANCE TESTS - THE BONFERRONI METHOD .10. [J].
BLAND, JM ;
ALTMAN, DG .
BRITISH MEDICAL JOURNAL, 1995, 310 (6973) :170-170
[6]   GENOMIC SEQUENCE FOR HUMAN PROINTERLEUKIN-1-BETA - POSSIBLE EVOLUTION FROM A REVERSE TRANSCRIBED PROINTERLEUKIN-1-ALPHA GENE [J].
CLARK, BD ;
COLLINS, KL ;
GANDY, MS ;
WEBB, AC ;
AURON, PE .
NUCLEIC ACIDS RESEARCH, 1986, 14 (20) :7897-7914
[7]   Epic and citation: Studies on the sources of the 'Odyssee' [J].
Clay, JS .
CLASSICAL WORLD, 2001, 94 (04) :407-408
[8]   INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AND MULTIPLE-SCLEROSIS [J].
CRUSIUS, JBA ;
PENA, AS ;
VANOOSTEN, BW ;
BIOQUE, G ;
GARCIA, A ;
DIJKSTRA, CD ;
POLMAN, CH .
LANCET, 1995, 346 (8980) :979-980
[9]  
DANIS VA, 1995, CLIN EXP IMMUNOL, V99, P303
[10]   The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1 [J].
Dinarello, CA .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (10) :732-734